Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Hepatobiliary disorders – page 14

  • 357 clinical trials
  • 141 recruiting
  • 239 conditions
  • 26 countries

Conditions in this area

239 conditions with trials, the busiest first

Hepatocellular carcinoma89Cholangiocarcinoma38Hepatic cirrhosis25Metabolic dysfunction-associated steatohepatitis22Colorectal cancer20Non-alcoholic steatohepatitis17Chronic hepatitis B16Hepatitis D14Primary biliary cholangitis14Cholangitis sclerosing12Endometrial cancer12Non-small cell lung cancer12Alpha-1 antitrypsin deficiency11Gastric cancer11Malignant melanoma11Biliary neoplasm10Hepatitis B10Breast cancer9Ovarian cancer9Bile duct cancer8Gallbladder cancer8Hepatic cancer8Pancreatic carcinoma8Adenocarcinoma pancreas7+215

Clinical trials in Hepatobiliary disorders

357 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

357 clinical trials

Hepatocellular carcinoma

Not yet recruiting

Study of durvalumab and tremelimumab with or without hepatic arterial infusion of gemcitabine and oxaliplatin in patients with high tumor burden hepatocellular carcinoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Unicancer

Liver abscess

Not yet recruiting

Study comparing 3-week versus 6-week antibiotic treatment for patients with drained pyogenic liver abscess

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Amikacin Sulfate
  • Sponsor:Assistance Publique Hopitaux De Paris

Hepatic lesion

Not yet recruiting

Safety and Effectiveness of Intravenous Sonazoid for Contrast-Enhanced Liver Ultrasound in Children with Focal Liver Lesions

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Perflubutane
  • Sponsor:GE Healthcare Limited

Hepatocellular carcinoma+5

Not yet recruiting

Study on the Safety and Effectiveness of CEB-01 for Children with Resectable Tumors

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:0–17 years
  • Substances:7-Ethyl-10-Hydroxycamptothecin
  • Sponsor:Cebiotex S.L.

Cholangiocarcinoma

Not yet recruiting

Study of Ivosidenib, Durvalumab, and Gemcitabine/Cisplatin for Patients with Advanced Cholangiocarcinoma with IDH1 Mutation

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Institut De Recherches Internationales Servier IRIS

Hepatitis alcoholic

Not yet recruiting

Study on the Effectiveness of N-Acetylcysteine and Methylprednisolone for Patients with Severe Acute Alcoholic Hepatitis

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Acetylcysteine
  • Sponsor:Asociacion Instituto De Investigacion Sanitaria Bioaraba

Gastric cancer+6

Not yet recruiting

Study on 68Ga-FAPI-46 PET Imaging for Patients with Gastrointestinal Cancers

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:(S)-2,2',2''-(10-(2-(4-(3-((4-(2-(2-Cyano-4,4-Difluoropyrrolidin-1-Yl)-2-Oxoethylcarbamoyl)-Quinolin-6-Yl)(Methyl)Amino)-Propyl)Piperazin-1-Yl)-2-Oxoethyl)-68Ga-[1,4,7,10]-Tetraazacyclododecane-1,4,7-Triyl)Triacetate
  • Sponsor:Universitaetsklinikum Essen AöR

Metabolic dysfunction-associated steatohepatitis+1

Not yet recruiting

Study of Fecal Microbiota Capsules for Treating Non-Alcoholic Steatohepatitis in Patients

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Allogeneic Faecal Microbiota, Pooled
  • Sponsor:Mikrobiomik Healthcare Company S.L.

Intraductal papillary mucinous neoplasm

Not yet recruiting

Study Comparing Secretin Synthetic Human and Endoscopic Aspiration Techniques for Analyzing Pancreatic Cancer in Patients with Intraductal Papillary Mucinous Neoplasia

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:SECRETIN SYNTHETIC HUMAN
  • Sponsor:Fundacio De Recerca Clinic Barcelona-Institut D’investigacions Biomediques August Pi I Sunyer

Obstructive pancreatitis+1

Not yet recruiting

Study on Ursodeoxycholic Acid to Prevent Recurrence of Acute Biliary Pancreatitis in Patients After Gallstone-Related Episode

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Ursodeoxycholic Acid
  • Sponsor:Hospital General Universitario Dr. Balmis

Congenital absence of bile ducts

Not yet recruiting

Study on Obeticholic Acid for Children with Biliary Atresia After Kasai Procedure

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Substances:Obeticholic Acid
  • Sponsor:Intercept Pharmaceuticals Inc.

Hepatic cirrhosis

Not yet recruiting

Study on Human Serum Albumin and Sodium Chloride for Patients with Liver Cirrhosis and Ascites

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Human Serum Albumin
  • Sponsor:European Foundation For The Study Of Chronic Liver Failure

Substances studied in this area

The therapies tested most often in Hepatobiliary disorders trials.

Durvalumab37 clinical trialsBevacizumab29 clinical trialsAtezolizumab27 clinical trialsCisplatin26 clinical trialsLenvatinib22 clinical trialsTremelimumab22 clinical trialsGemcitabine20 clinical trialsInfliximab15 clinical trialsMycophenolate Mofetil15 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.